These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10371531)

  • 21. The role of IL-12 and TNF-alpha in AIDP and AMAN.
    Deng H; Yang X; Jin T; Wu J; Hu LS; Chang M; Sun XJ; Adem A; Winblad B; Zhu J
    Eur J Neurol; 2008 Oct; 15(10):1100-5. PubMed ID: 18717726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome.
    Ye Y; Li SL; Li YJ
    Transfus Med; 2015 Apr; 25(2):79-84. PubMed ID: 25515056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of matrix metalloproteinases-2 and -9 with proinflammatory cytokines in Guillain-Barré syndrome.
    Nyati KK; Prasad KN; Verma A; Paliwal VK
    J Neurosci Res; 2010 Dec; 88(16):3540-6. PubMed ID: 20936699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin.
    Sater RA; Rostami A
    Neurology; 1998 Dec; 51(6 Suppl 5):S9-15. PubMed ID: 9851724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour necrosis factor-alpha and other cytokines in Guillain-Barré syndrome.
    Exley AR; Smith N; Winer JB
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1118-20. PubMed ID: 8089682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome.
    Ravasio A; Pasquinelli M; Currò Dossi B; Neri W; Guidi C; Gessaroli M; Rasi F; Fabbri R; Mazzini G; Rebucci GG
    Ital J Neurol Sci; 1995 Oct; 16(7):487-92. PubMed ID: 8749707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
    Kleyweg RP; van der Meché FG
    J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):957-60. PubMed ID: 1800666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Guillain-Barré syndrome in children treated with intravenous immunoglobulin].
    Andersen UM
    Ugeskr Laeger; 1993 Oct; 155(42):3392-4. PubMed ID: 8259633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical variants of Guillain-Barre syndrome: some aspects of differential diagnosis.
    Dididze MN
    Georgian Med News; 2009 Jan; (166):48-51. PubMed ID: 19202218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Alteration of cytokines in serum and cerebrospinal fluid before and after high-dose immunoglobulin therapy in patients with West syndrome].
    Matsuura R; Hamano SI; Hirata Y; Oba A; Kumagai Y; Suzuki K; Koichihara R; Kikuchi K; Tanaka M; Minamitani M
    No To Hattatsu; 2016 Jul; 48(4):247-51. PubMed ID: 30010305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immunoglobulin and Guillain-Barré syndrome.
    Harel M; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):281-7. PubMed ID: 16391403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Guillain-Barré syndrome and CIDP.
    van Doorn PA
    J Peripher Nerv Syst; 2005 Jun; 10(2):113-27. PubMed ID: 15958124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of Guillain-Barré Syndrome].
    Nomura K
    Brain Nerve; 2015 Nov; 67(11):1397-410. PubMed ID: 26560955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange.
    Fujimaru T; Ito S; Masuda H; Oana S; Kamei K; Ishiguro A; Kato H; Abe J
    Cytokine; 2014 Dec; 70(2):156-60. PubMed ID: 25082649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
    van Doorn PA; Kuitwaard K; Jacobs BC
    J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain.
    Leontyev D; Neschadim A; Branch DR
    Transfusion; 2014 Nov; 54(11):2871-9. PubMed ID: 24826802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immune globulin in the Guillain-Barré syndrome.
    van der Meché FG
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):43-7. PubMed ID: 8033434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.